Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cresco LabsCRLBF -5.46%29 EV-to-OCF is 17.03 as of Sep. 04, 2026, which is 48% above its 10-year median of 11.53. GuruFocus rates CRLBF with a GF Score™ of 29/100 and a GF Value™ of $0.87 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Cresco Labs ranks worse than 65.81% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Cresco Labs's Enterprise Value is $739.1 Mil.
Cresco Labs's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $43.4 Mil. Therefore, Cresco Labs's EV-to-OCF for today is 17.03.
The historical rank and industry rank for Cresco Labs's EV-to-OCF or its related term are showing as below:
CRLBF'
s EV-to-OCF Range Over the Past 10 Years
Min: -1658.57 Med: 11.53 Max: 53089.99
Current: 17.03
During the past 13 years, the highest EV-to-OCF of Cresco Labs was 53089.99. The lowest was -1658.57. And the median was 11.53.
CRLBF's EV-to-OCF is ranked worse than 65.81% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 10.355
vs CRLBF: 17.03
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cresco Labs's PE Ratio (TTM) for today is calculated as:
Cresco Labs's share price for today is $0.7412.
Cresco Labs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.290.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cresco Labs EV-to-OCF Related Terms
Cresco Labs EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Cresco Labs's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cresco Labs's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cresco Labs EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cresco Labs's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Cresco Labs's EV-to-OCF falls into.
Cresco Labs's current Enterprise Value is $739.1 Mil.
Cresco Labs's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $43.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cresco Labs (CRLBF) has a EV-to-OCF of 17.03 as of Sep. 04, 2026. This is 48% above median its historical median of 11.53. According to the industry distribution chart, Cresco Labs ranks #662 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 65.8%.
Is Cresco Labs' EV-to-OCF too high?
Cresco Labs' current EV-to-OCF of 17.03 is 48% above median its 10-year median of 11.53. The Drug Manufacturers industry median EV-to-OCF is 10.36. Cresco Labs' value of 17.03 is 64.5% above this industry median. Based on the distribution chart, Cresco Labs ranks #662 out of 1006 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cresco Labs has a GF Score™ of 29/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cresco Labs' EV-to-OCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cresco Labs ranks #662 out of 1006 companies for EV-to-OCF. This places Cresco Labs in the lower half of its industry. The industry median EV-to-OCF is 10.36. Cresco Labs' value of 17.03 is 64.5% above this benchmark. While the company's 10-year median is 11.53 vs. the industry median of 10.36, Cresco Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.36, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cresco Labs's current EV-to-OCF of 17.03 is 64.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cresco Labs's current EV-to-OCF is 17.03, which is 48% above median its own 10-year median of 11.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cresco Labs stock overvalued right now?
Based on GuruFocus' analysis, Cresco Labs (CRLBF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.87, compared to a current price of $0.74 — trading 14.8% below its estimated fair value. The current EV-to-OCF is 17.03, which is 48% above median its 10-year median of 11.53 and 64.5% above the Drug Manufacturers industry median of 10.36. Cresco Labs' overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Cresco Labs (CRLBF), the current EV-to-OCF is 17.03 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cresco Labs (CRLBF) Overvalued in 2026?
Based on GuruFocus' analysis, Cresco Labs stock appears to be undervalued.
The current stock price of $0.74 is trading 14.8% below its estimated GF Value™ of $0.87.
GuruFocus considers Cresco Labs to be Modestly Undervalued.
Key valuation signals for CRLBF:
EV-to-OCF: 17.03 (48% above median its 10-year median of 11.53)
GF Value™: $0.87 vs. price of $0.74 (14.8% below fair value)
Industry Position: 64.5% above the Drug Manufacturers median (#662 of 1006)
No single metric tells the full story. See the CRLBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cresco Labs Inc is a vertically-integrated multi-state cannabis operator in the United States licensed to cultivate, manufacture, and sell retail and medical cannabis products through Sunnyside, Cresco Lab's national dispensary brand, and others. The company operates in one segment: the cultivation, manufacturing, distribution, and sale of cannabis. The company's brand includes: Cresco, High Supply, FloraCal Farms, Good News, Wonder Wellness Co., Mindy's, and Remedi.
29GF Score
Get the complete analysis for CRLBF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRLBF has been successfully added to your 
